| dc.contributor | Hospital General de Granollers |
| dc.contributor.author | Nogué Xarau, Santiago |
| dc.contributor.author | Martínez Sánchez, Lidia |
| dc.contributor.author | Garcia-Pelaez, Milagros |
| dc.contributor.author | Pi Sala, Núria |
| dc.contributor.author | SALGADO, EMILIO |
| dc.contributor.author | Fernández de Gamarra Martínez, Edurne |
| dc.contributor.author | Gispert Ametller, Maria Angels |
| dc.contributor.author | Aguilar Salmerón, Raquel |
| dc.date.accessioned | 2025-09-19T11:33:39Z |
| dc.date.available | 2025-09-19T11:33:39Z |
| dc.date.issued | 2025-08-19 |
| dc.identifier.citation | Nogué-Xarau S, Martínez-Sánchez L, García-Peláez M, Fernández de Gamarra-Martínez E, Pi-Sala N, Gispert-Ametller À, et al. N-acetylcysteine: 50 years since the discovery of an antidote that has changed the prognosis of acetaminophen poisoning. Farm Hosp. 2025 Aug 19:S1130-6343(25)00109-6. |
| dc.identifier.issn | 1130-6343 |
| dc.identifier.uri | http://hdl.handle.net/11351/13694 |
| dc.description | Acetaminophen; Acetylcysteine; Liver toxicity |
| dc.description.abstract | Acetaminophen is one of the most widely used drugs in clinical practice due to its analgesic and antipyretic properties. However, overdose is one of the leading causes of severe acute liver failure. N-acetylcysteine, introduced as an antidote in 1974, has revolutionized the management of this intoxication by reducing hepatotoxicity and mortality associated with acetaminophen toxicity. At the end of the 19th century, acetaminophen was identified as the main active metabolite of phenacetin and acetanilide. Its therapeutic use began to gain popularity in the 1950s and later became one of the main drugs involved in suicide attempts, particularly among adolescents and young adults. Acetaminophen-induced hepatotoxicity was first described in 1966, establishing that an overdose could lead to fulminant hepatic necrosis. In 1975, Rumack and Matthew published a nomogram that allowed stratification of hepatic toxicity risk based on plasma drug levels. The mechanism of hepatotoxicity was elucidated in the early 1970s when it was discovered that acetaminophen is metabolized by cytochrome P450 into a highly reactive intermediate, N-acetyl-p-benzoquinoneimine, which is normally neutralized by hepatic glutathione. In overdose situations, glutathione depletion leads to hepatic necrosis. Based on these findings, sulfhydryl-containing agents such as cysteamine and methionine were introduced as antidotes, but N-acetylcysteine ultimately proved to be the most effective treatment. Since its introduction, N-acetylcysteine administration protocols have evolved to optimize efficacy and minimize adverse effects. Protocols such as the Scottish and Newcastle Acetylcysteine Protocol and the Two Bags regimen have simplified dosing and reduced the incidence of anaphylactoid reactions. Over the past 50 years, N-acetylcysteine has saved thousands of lives and remains the gold-standard antidotal treatment for acetaminophen poisoning. |
| dc.language.iso | spa |
| dc.publisher | Elsevier |
| dc.relation.ispartofseries | Farmacia hospitalaria; |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Paracetamol |
| dc.subject | Acetilcisteïna |
| dc.subject | Hepatotoxicitat |
| dc.subject.mesh | Acetylcysteine |
| dc.subject.mesh | Acetaminophen |
| dc.subject.mesh | Liver Failure, Acute |
| dc.title | N-acetylcysteine: 50 years since the discovery of an antidote that has changed the prognosis of acetaminophen poisoning |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1016/j.farma.2025.07.005 |
| dc.subject.decs | acetilcisteína |
| dc.subject.decs | acetaminofén |
| dc.subject.decs | fracaso hepático agudo |
| dc.relation.publishversion | https://doi.org/10.1016/j.farma.2025.07.005 |
| dc.type.version | info:eu-repo/semantics/acceptedVersion |
| dc.audience | Professionals |
| dc.contributor.authoraffiliation | [Nogué-Xarau S] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Fundación Española de Toxicología Clínica, Barcelona, Spain. [Martínez-Sánchez L] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Servei d’Urgències, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain. [García-Peláez M] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Fundación Española de Toxicología Clínica, Barcelona, Spain. Servei de Farmàcia, Hospital General de Granollers, Granollers, Spain. [Fernández de Gamarra-Martínez E] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Servei de Farmàcia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Pi-Sala N] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Servei de Farmàcia, Hospital de Figueres, Figueres, Spain. [Gispert-Ametller À] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Servei d’Urgències, Hospital Universitari Doctor Josep Trueta, Girona, Spain. [Salgado-García E] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Àrea d’Urgències, Hospital Clínic, Barcelona, Spain. [Aguilar-Salmerón R] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Servei de Farmàcia, Hospital Universitari Doctor Josep Trueta, Girona, Spain |
| dc.identifier.pmid | 40835518 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |